Peyronie's disease: Intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging

International Urology and Nephrology

Volumn 29, Issue 4, 1997, Pages 465-471

  Polat, O ^a   Gul O ^a   Ozbey I ^a   Ozdikici M ^a   Bayraktar, Y ^a  

^a ATATURK UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PEYRONIE DISEASE;

EID: 0030657819     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02551115     Document Type: Article

References (18)

1. Schneider, H. J., Rugendorf, E. W., Röhrbom, C.: Pathogenesis, diagnosis and therapy of induratio penis plastica (IPP). Int. Urol. Nephrol., 17, 235 (1985).
2. Smith, B. H.: Peyronie's disease. Am. J. Clin. Pathol., 45, 670 (1966).
3. Chesney, J.: Peyronie's disease. Br. J. Urol., 47, 209 (1975).
4. Devine, C. J., Jordan, G. H., Somers, K. D.: Peyronie's disease: Cause and surgical treatment. AUA Today, 2, 1 (1989).
5. Devine, C. J., Somers, K. D., Wright, G. L.: A working model for the genesis of Peyronie's disease derived from its pathobiology. J. Urol., 139 (Abstract, 495) (1988).
6. Abbas, A. K., Lichtman, A. H., Pober, J. S.: Cytokines. In: Abbas, A. K., Lichtman, A. H., Pober, J. S. (eds): Cellular and Molecular Immunology. Second edition. W. B. Saunders Company, Philadelphia 1991, pp. 240-260.
7. Duncan, M. R., Berman, B., Nseyo, U. O.: Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferonsalpha, -beta and -gamma. Scand. J. Urol. Nephrol., 25, 89 (1991).
8. Pryor, J. P., Farrell, C: R.: Controlled clinical trial of vitamin E in Peyronie's disease. Prog. Reprod. Biol. Med., 9, 41 (1983).
9. Oyar, O., Apaydin, E., Sevinç, E., Erhan, Ö.: Magnetic resonance imaging in Peyronie's disease. Computerized Tomography Bulletin, 3/2, 131 (1994).
10. Smith, B. H.: Peyronie's disease. Am. J. Clin. Pathol., 45, 670 (1966).
11. Smith, B. H.: Subclinical Peyronie's disease. Am. J. Clin. Pathol., 52, 385 (1969).
12. Ralph, D. J., Brooks, M. D., Bottazzo, G. F., Pryor, J. P.: The treatment of Peyronie's disease with tamoxifen. Br. J. Urol., 70, 648 (1992).
13. Devine, C. J., Horton, C. E.: The surgical treatment of Peyronie's disease with a dermal graft. J. Urol., 111, 44 (1974).
14. Berman, B., Duncan, M. R.: Short-term keloid treatment in vivo with human interferonalpha 2B results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan and collagenase production in vitro. J. Am. Acad. Dermatol., 21, 694 (1989).
15. Duncan, M. R., Berman, B.: Persistence of a reduced collagen-producing phenotype in cultured sclerodermal fibroblasts after short-term exposure to interferons. J. Clin. Invest., 79, 1318 (1987).
16. Kanari, V. M., Heino, J., Vuorio, T., Vuorio, E.: Interferon-alpha and interferon-gamma reduced excessive collagen synthesis and procollagen mRNA levels of sclerodermal fibroblasts in culture. Biochem. Biophys. Acta, 968, 45 (1988).
17. Abbas, A. K., Lichtman, A. H., Pober, J. S.: Immunity to tumors. In: Abbas, A. K., Lichtman, A. H., Pober, J. S. (eds): Cellular and Molecular Immunology. Second edition. W. B. Saunders Company, Philadelphia 1991, pp. 357-375.
18. Tonaka, K. T., Yoshioka, C., Bieberich, J. G.: The role of the major histocompatibility complex class 1 antigens in tumor growth and metastasis. Ann. Rev. Immunol., 6, 359 (1988).